Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6042339 | 1.00 | MEN1 (0.48) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| Zinc Ion SCHEMBL30416657 | 0.98 | MEN1 (0.47) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL217068 | 0.96 | MEN1 (0.51) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL7167518 | 0.96 | MEN1 (0.51) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL17393650 | 0.95 | MEN1 (0.45) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL23015072 | 0.94 | MEN1 (0.54) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL1069647 | 0.94 | MEN1 (0.54) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL2786532 | 0.94 | MEN1 (0.54) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL1008189 | 0.94 | MEN1 (0.54) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL203262 | 0.94 | MEN1 (0.54) | MEN1KMT2AKDM4CL3MBTL1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1394 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117486929-A | Substituted alkyl germanium compound and modularized synthesis method thereof | 西安交通大学 | 2024-02-02 | — | — | CN | claimed |
| CN-114751852-B | Preparation method of silodosin key intermediate | 山西库邦生物医药科技有限公司 | 2023-09-15 | — | — | CN | claimed |
| CN-114751852-A | Preparation method of key intermediate of silodosin | 山西库邦生物医药科技有限公司 | 2022-07-15 | — | — | CN | claimed |
| CN-112645971-B | Method for directly preparing alkyl borate compound from alkyl halide | 中国科学院兰州化学物理研究所 | 2021-12-24 | — | — | CN | claimed |
| CN-109970534-B | Method for synthesizing peach fruit moth sex pheromone | 中国农业大学 | 2020-11-13 | — | — | CN | claimed |
| CN-102295558-B | Sex pheromone components of apocheima cinerarius erschoff, synthesis and identification method thereof | XINJIANG TECH INST PHYSICS CAS | 2013-11-13 | — | — | CN | claimed |
| CN-102295558-A | Sex pheromone components of apocheima cinerarius erschoff, synthesis and identification method thereof | — | 2011-12-28 | — | — | CN | claimed |
| US-6448353-B1 | ANIONIC SOLUTION POLYMERIZATION OF TEMPERATURE SENSITIVE MONOMERS UNDER PLUG FLOW AND TEMPERATURE CONTROLLED CONDITIONS; MINIMIZING SIDE REACTIONS; NARROW POLYDISPERSITY; TAILORING FOR SPECIFIC APPLICATIONS | 3M INNOVATIVE PROPERTIES COMPANY | 2002-09-10 | — | — | US | claimed |
| EP-4739682-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | Janssen Pharmaceutica NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| EP-3761989-B1 | IMIDAZODIAZEPINEDIONES AND METHODS OF USE THEREOF | GFB ABC LLC (US) | 2026-05-13 | — | — | EP | disclosed |
| EP-4737443-A1 | SALT-INDUCIBLE KINASE INHIBITORY COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | Tanabe Pharma Corporation (JP) | 2026-05-06 | — | — | EP | disclosed |
| EP-3814356-B1 | TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS | ZHEJIANG VIMGREEN PHARMACEUTICALS LTD (CN) | 2026-03-11 | — | — | EP | disclosed |
| US-20260062387-A1 | SALT-INDUCIBLE KINASE INHIBITOR COMPOUND AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2026-03-05 | — | — | US | disclosed |
| US-12559486-B2 | Tau-protein targeting compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-4188374-A | Attractant for the potato moth and the preparation of the former | Nederlandse Organisatie Voor Toegepast-Natuurwetenschappe-Lijk Onderzoek Ten Behoeve Van Nijverheid, Handel En-Verkeer (NL) | 1980-02-12 | — | — | US | disclosed |
| US-4180570-A | 17β-Hydroxy-4-androsten-3-ones and process for the preparation thereof | SCHERING AKTIENGESELLSCHAFT (DE) | 1979-12-25 | — | — | US | disclosed |
| US-4112236-A | Interphenylene 8-aza-9-dioxothia-11,12-secoprostaglandins | MERCK & CO., INC. (US) | 1978-09-05 | — | — | US | disclosed |
| US-4090027-A | APPETITE SUPPRESSANTS | HOFFMANN-LA ROCHE INC. (US) | 1978-05-16 | — | — | US | disclosed |
| US-4077978-A | APPETITE SUPPRESSANTS | HOFFMANN-LA ROCHE INC. (US) | 1978-03-07 | — | — | US | disclosed |
| US-3996374-A | Isoindole derivatives as appetite suppressants | HOFFMANN-LA ROCHE INC. (US) | 1976-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062387-A1 | SALT-INDUCIBLE KINASE INHIBITOR COMPOUND AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME | SIK1, SIK3, SIK2 | MEN1 3747/4885KMT2A 1971/4885KDM4C 2173/4885 |
| US-12559486-B2 | Tau-protein targeting compounds and associated methods of use | UBQLN2, UBQLN1, CRBN | MEN1 1955/4885KMT2A 767/4885KDM4C 558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.